<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Membranous nephropathy: Treatment and prognosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Membranous nephropathy: Treatment and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Membranous nephropathy: Treatment and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">An S De Vriese, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jack FM Wetzels, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Cattran, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fernando C Fervenza, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H161669957"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Membranous nephropathy (MN) is among the most common causes of the nephrotic syndrome in nondiabetic adults, accounting for up to one-third of biopsy diagnoses in some regions. The term MN reflects the pattern of histologic change noted on light microscopy: glomerular basement membrane (GBM) thickening with little or no cellular proliferation or infiltration. </p><p>MN in adults is most often primary (approximately 75 to 80 percent of cases) and caused by circulating autoantibodies against podocyte antigens. In approximately 20 to 25 percent of cases in adults, the MN lesion is associated with various disorders, including infections (such as hepatitis B and syphilis); autoimmune diseases; malignancies; allogeneic hematopoietic stem cell transplantation; and the use of certain drugs such as nonsteroidal antiinflammatory drugs (NSAIDs), alpha-lipoic acid, and certain traditional medicines.</p><p>The treatment and prognosis of MN in the native kidney will be reviewed here. Other aspects of MN are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/117886.html" rel="external">"Membranous nephropathy: Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7341.html" rel="external">"Membranous nephropathy and kidney transplantation"</a>.)</p><p></p><p class="headingAnchor" id="H2458510228"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>The phospholipase A2 receptor (PLA2R) is the most important target antigen in patients with primary MN (see  <a class="medical medical_review" href="/z/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Phospholipase A2 receptor'</a>). The following terminology will be used throughout this topic:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PLA2R-associated MN</strong> – MN with <strong>either</strong> positive immunofluorescence staining for PLA2R antigen on kidney biopsy <strong>or</strong> with detectable serum anti-PLA2R antibodies. The most sensitive technique to diagnose PLA2R-associated MN is immunostaining of the kidney biopsy for PLA2R antigen. In the majority of patients with PLA2R-associated MN, circulating autoantibodies directed against PLA2R can be detected in the serum.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-PLA2R-associated MN</strong> – MN with neither immunofluorescence staining for PLA2R antigen on kidney biopsy nor detectable serum anti-PLA2R antibodies. Patients with non-PLA2R-associated MN may be positive for other target antigens associated with MN, such as thrombospondin type-1 domain-containing 7A (THSD7A), neural epidermal growth factor-like 1 (NELL-1), semaphorin 3B (Sema3B), protocadherin 7 (PCDH7), and other novel antigens [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Other antigens'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-PLA2R antibody positive</strong> – In a patient with PLA2R-associated MN, circulating autoantibodies directed against PLA2R are detectable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-PLA2R antibody negative</strong> – In a patient with PLA2R-associated MN, circulating autoantibodies directed against PLA2R are not detectable. In these patients it is likely that the kidneys act as a "sink" by binding all available anti-PLA2R autoantibodies. If disease activity persists, anti-PLA2R antibodies may become detectable with longer follow-up [<a href="#rid2">2</a>]. Alternatively, some patients with undetectable antibodies may have already developed an immunologic remission; in such patients, a gradual decrease in proteinuria will become apparent.</p><p></p><p class="headingAnchor" id="H2423056852"><span class="h1">PRETREATMENT CONSIDERATIONS</span></p><p class="headingAnchor" id="H1440328614"><span class="h2">Likelihood of spontaneous remission</span><span class="headingEndMark"> — </span>In view of the potential toxicity of the drugs used to treat primary MN, the decision to initiate therapy is based, in part, upon an understanding of the natural history of untreated patients, with and without features of the nephrotic syndrome at presentation [<a href="#rid3">3-6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Spontaneous complete remission of proteinuria occurs in 5 to 30 percent at five years [<a href="#rid4">4-7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spontaneous partial remission (proteinuria ≤2 g/day) occurs in 25 to 40 percent at five years [<a href="#rid4">4-6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The occurrence of end-stage kidney disease (ESKD) in untreated patients with nephrotic syndrome is approximately 14 percent at five years, 35 percent at 10 years, and 41 percent at 15 years [<a href="#rid3">3,6</a>]. However, among untreated patients who remain non-nephrotic for the duration of their disease, the rate of ESKD at 10 years may be as low as 2 percent [<a href="#rid8">8</a>].</p><p></p><p class="headingAnchor" id="H3732555512"><span class="h2">Risk factors for disease progression</span><span class="headingEndMark"> — </span>In view of the often indolent clinical course and toxicity of available therapies, immunosuppressive agents should be considered only in patients with primary MN who are most at risk for progressive disease, have severe symptomatic nephrotic syndrome, or are at risk for or have complications of nephrotic syndrome. (See <a class="local">'Which patients need treatment'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Clinical features associated with a higher risk of developing ESKD include nephrotic-range proteinuria (particularly if protein excretion exceeds 8 to 10 g/day) and an increased serum creatinine at presentation [<a href="#rid4">4,9-12</a>]. Although male sex and older age at onset have been associated with a higher risk of developing ESKD, this higher risk is mostly explained by the severity of disease (ie, higher proteinuria, lower glomerular filtration rate) [<a href="#rid13">13,14</a>].</p><p></p><p class="bulletIndent1">Conversely, non-nephrotic-range proteinuria, a progressive decline in protein excretion, and presentation with normal kidney function have been associated with a relatively benign course [<a href="#rid3">3,5,8,15-17</a>]. In addition, patients of Japanese ancestry seem to have a better long-term prognosis than other ancestries [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biomarkers</strong> – Certain biomarkers have been associated with an increased risk of disease progression among patients with primary MN:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Serum anti-phospholipase A2 receptor (PLA2R) antibody</strong> – Circulating autoantibodies to the M-type PLA2R are present in approximately 70 to 80 percent of patients with primary MN. Among patients with PLA2R-positive primary MN, a high level of anti-PLA2R antibody at the time of diagnosis has been associated in cross-sectional analysis with an increased risk for progressive loss of kidney function [<a href="#rid18">18-21</a>], a lower risk of spontaneous remission [<a href="#rid18">18,22</a>], and, among patients with non-nephrotic proteinuria, an increased risk for developing nephrotic proteinuria [<a href="#rid23">23</a>]. However, because the thresholds used to define a high titer varied in these studies, it remains unclear what specific antibody level should be used to predict the risk of disease progression. (See  <a class="medical medical_review" href="/z/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Phospholipase A2 receptor'</a>.)</p><p></p><p class="bulletIndent2">Conversely, a low titer or absence of anti-PLA2R antibody is associated with a higher likelihood of spontaneous clinical remission [<a href="#rid17">17,18,24,25</a>]. Similarly, a reduction in anti-PLA2R antibody levels within the first six months after diagnosis, with or without treatment, is also commonly associated with clinical remission [<a href="#rid17">17,26</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Serum anti-thrombospondin type-1 domain-containing 7A (THSD7A) antibody</strong> – Circulating autoantibodies to THSD7A are present in approximately 3 percent of patients with primary MN [<a href="#rid27">27,28</a>]. Data on the prognostic role of anti-THSD7A antibody levels are limited [<a href="#rid27">27,29</a>]. The available data suggest that, similarly to anti-PLA2R antibodies, anti-THSD7A antibodies correlate with disease activity [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Urine low-molecular-weight proteins</strong> – Urinary excretion of the low-molecular-weight proteins beta-2 microglobulin and alpha-1 microglobulin has been shown to correlate with disease progression in patients with primary MN [<a href="#rid30">30,31</a>]. The prognostic utility of these markers has not been directly compared with that of serum anti-PLA2R antibody levels. These markers have not been shown to predict the response to immunosuppressive therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histologic findings </strong>– Histologic findings are frequently regarded as important predictors of outcome, as the risk of progression is increased in patients with glomerular scarring (segmental and/or global glomerulosclerosis) and correlates more closely with the severity of the tubulointerstitial disease than with the degree of glomerular injury [<a href="#rid9">9,32,33</a>]. This observation is typical of most glomerular disease. (See  <a class="medical medical_review" href="/z/d/html/7181.html" rel="external">"Secondary factors and progression of chronic kidney disease", section on 'Tubulointerstitial fibrosis'</a>.)</p><p></p><p class="headingAnchor" id="H4114528904"><span class="h1">GENERAL MEASURES IN ALL PATIENTS</span><span class="headingEndMark"> — </span>General supportive measures in all patients with MN include dietary sodium and protein restriction, blood pressure control, minimization of proteinuria with renin-angiotensin system inhibition, treatment of dyslipidemia, and, in select patients, anticoagulation. Sodium-glucose cotransporter 2 (SGLT2) inhibitors may also be of benefit, although formal studies in nephrotic patients are lacking. Other aspects of therapy include diuretics to control edema and maintenance of adequate nutrition [<a href="#rid34">34</a>]. This approach is consistent with the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases [<a href="#rid35">35</a>]. These issues are discussed in greater detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>Dietary sodium and protein restriction (see  <a class="medical medical_review" href="/z/d/html/7178.html" rel="external">"Dietary recommendations for patients with nondialysis chronic kidney disease", section on 'Salt intake'</a> and  <a class="medical medical_review" href="/z/d/html/7178.html" rel="external">"Dietary recommendations for patients with nondialysis chronic kidney disease", section on 'Protein intake'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antihypertensive therapy (see  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renin-angiotensin system inhibition (see  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Renin-angiotensin system inhibitors'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SGLT inhibitors (see  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Patients with proteinuria'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lipid lowering (See  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Dyslipidemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anticoagulation (see  <a class="medical medical_review" href="/z/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome", section on 'Patients with membranous nephropathy'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of edema (see  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Volume overload'</a>)</p><p></p><p class="headingAnchor" id="H1525902866"><span class="h1">INITIAL THERAPY FOR PRIMARY MN</span></p><p class="headingAnchor" id="H2496070858"><span class="h2">Which patients need treatment</span><span class="headingEndMark"> — </span>In patients with primary MN, our approach to initial therapy is based upon an assessment of the patient's risk of progressive disease, which we determine using both clinical and immunologic parameters  (<a class="graphic graphic_table graphicRef126999" href="/z/d/graphic/126999.html" rel="external">table 1</a>) [<a href="#rid36">36</a>]:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with primary MN, regardless of phospholipase A2 receptor (PLA2R) status, we consider patients who present with <strong>two or more </strong>of the following features to be at <strong>very high risk</strong> for progressive disease:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum creatinine ≥1.5 mg/dL [≥133 micromol/L] considered to be due to active MN</p><p class="bulletIndent2"><span class="glyph">•</span>Progressive decline in kidney function (eg, decrease in estimated glomerular filtration rate [eGFR] ≥25 percent from baseline over the prior two years) considered to be due to active MN</p><p class="bulletIndent2"><span class="glyph">•</span>Severe, disabling, or life-threatening nephrotic syndrome (defined by the presence of a serum albumin &lt;2.5 g/dL [if measured by bromocresol green methods] or &lt;2.0 g/dL [if measured by bromocresol purple methods] and refractory edema, or a thromboembolic event)</p><p></p><p class="bulletIndent1">In such patients, we recommend treatment with immunosuppressive therapy, and treatment with immunosuppressive agents should<strong> not</strong> be delayed unless contraindicated. (See <a class="local">'High or very high risk of progression'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with primary MN who present with normal kidney function <strong>and </strong>do not have severe, disabling, or life-threatening nephrotic syndrome, we recommend treating with general supportive measures (including renin-angiotensin system inhibition) only for <strong>three to six months</strong> and monitoring for signs of disease progression (see <a class="local">'General measures in all patients'</a> above). During this observation period, we measure 24-hour urine protein excretion, serum creatinine (with determination of eGFR), and serum albumin at baseline and every one to three months depending upon the clinical severity at presentation. If the patient has PLA2R-associated primary MN (ie, serum anti-PLA2R antibody positive or positive immunostaining for PLA2R on kidney biopsy), we monitor serum anti-PLA2R antibody titers by enzyme-linked immunosorbent assay (ELISA) to evaluate the immunologic activity of the disease. We typically monitor antibody levels every two to three months and consider more frequent monitoring in patients with high antibody levels (arbitrarily defined as ≥150 RU/mL).</p><p></p><p class="bulletIndent1">After <strong>three to six months of observation</strong> (or sooner if the patient has signs or symptoms of rapid disease progression), we stratify patients into the following categories of risk based upon an assessment of the temporal trends of these clinical and serologic parameters:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High risk</strong> – Patients with <strong>two or more</strong> of the following are considered to be at high risk for progressive disease:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Decrease in eGFR of ≥25 percent, not explained by other causes, <strong>at any time</strong> during the observation period</p><p class="bulletIndent3"><span class="glyph">-</span>Proteinuria &gt;8 g/day at the end of the observation period <strong>or </strong>persistent nephrotic syndrome (proteinuria &gt;3.5 g/day and serum albumin &lt;3.5 g/dL [if measured by bromocresol green methods] or &lt;3.0 g/dL [if measured by bromocresol purple methods])</p><p class="bulletIndent3"><span class="glyph">-</span>If the patient is anti-PLA2R antibody positive, serial anti-PLA2R antibody titers are high (arbitrarily defined as ≥150 RU/mL by the ELISA method) and not declining <strong>or</strong> are increasing to ≥150 RU/mL</p><p></p><p class="bulletIndent2">Patients at high risk of progression should be treated with immunosuppressive therapy without further delay, unless contraindicated. (See <a class="local">'High or very high risk of progression'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate risk</strong> – Patients with <strong>two or more </strong>of the following are considered to be at moderate risk for progressive disease:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Normal or stable (ie, &lt;25 percent decrease) eGFR over the three-to-six-month period</p><p class="bulletIndent3"><span class="glyph">-</span>Proteinuria persistently between 4 and 8 g/day at the end of observation period</p><p class="bulletIndent3"><span class="glyph">-</span>If the patient is anti-PLA2R antibody positive, serial anti-PLA2R antibody titers are &lt;150 RU/mL (by the ELISA method) <strong>and</strong> stable or increasing by &lt;25 percent over the six-month period</p><p></p><p class="bulletIndent2">Patients at moderate risk of progression may or may not require treatment with immunosuppressive therapy. Our approach to initial therapy varies depending upon the course of disease during the initial three to six-month observation period. (See <a class="local">'Moderate risk of progression'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Low risk</strong> – Patients with <strong>two or more </strong>of the following are considered to be at low risk for progressive disease:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Normal or stable eGFR (ie, &lt;25 percent decrease) over the three-to-six-month period</p><p class="bulletIndent3"><span class="glyph">-</span>Proteinuria &lt;4 g/day at the end of the observation period</p><p class="bulletIndent3"><span class="glyph">-</span>If the patient is anti-PLA2R antibody positive, serial anti-PLA2R antibody titers are low (arbitrarily defined as &lt;50 RU/mL by the ELISA method) or decreasing by ≥25 percent at three to six months</p><p></p><p class="bulletIndent2">Patients at low risk of progression do not require immunosuppressive therapy and can generally be managed with supportive measures only. (See <a class="local">'Low risk of progression'</a> below.)</p><p></p><p>In general, we do <strong>not </strong>give immunosuppressive therapy to patients if they have evidence of severe and irreversible kidney damage (ie, history of chronic kidney disease with a serum creatinine &gt;3.5 mg/dL [309 micromol/L] or eGFR &lt;30 mL/min/1.73 m<sup>2</sup> for &gt;3 months; kidney size less than 8 cm on kidney ultrasound; or evidence of severe interstitial fibrosis, tubular atrophy, or glomerulosclerosis on kidney biopsy), since immunosuppressive therapy is not likely to be effective in such patients. In such patients, we continue to administer general supportive measures and discuss future options for kidney replacement therapy. We also do <strong>not</strong> give immunosuppressive therapy to patients with concomitant severe or potentially life-threatening infections. (See <a class="local">'Patients with active infection'</a> below.)</p><p>While most patients with primary MN will be properly classified into one of the above risk categories based upon their clinical and immunologic parameters, there may be some exceptions that are not perfectly represented by this stratification system. In such cases, clinical judgment is required to assess the risk of disease progression. In general, the three parameters (proteinuria, eGFR, and anti-PLA2R antibody levels) evolve in concert, with changes in anti-PLA2R antibody levels typically preceding changes in the clinical parameters. If this paradigm does not apply (eg, a decline in eGFR is accompanied by a decline in anti-PLA2R antibody titer), then alternative causes (eg, superimposed disease, hemodynamic effects of renin-angiotensin system inhibitors, renal vein thrombosis) should be excluded first.</p><p>This risk stratification applies only to the likelihood of progressive kidney failure. It does not take into account the risks that may be associated with other complications of the nephrotic syndrome, such as worsening atherosclerosis due to hypercholesterolemia and thromboemboli due to the associated hypercoagulable state. Thus, in addition to preservation of kidney function, immunosuppressive therapy may be beneficial by shortening the overall exposure to the nephrotic state, thereby minimizing the risk of other complications. (See <a class="local">'General measures in all patients'</a> above.)</p><p>The rationale for our approach is based in part upon studies showing the importance of persistent proteinuria and change in kidney function over a six-month observation period in predicting the probability of progression to chronic kidney disease [<a href="#rid11">11,12</a>]. Models incorporating these clinical variables have estimated the risk of chronic kidney disease (defined as creatinine clearance ≤60 mL/min/1.73 m<sup>2</sup>) over five years to be 75, 50, and less than 8 percent for patients defined as high, moderate, and low risk, respectively [<a href="#rid12">12</a>]. However, such models do not apply to algorithms that also incorporate anti-PLA2R antibody levels.</p><p class="headingAnchor" id="H3192329019"><span class="h3">Clinical utility of anti-PLA2R antibody levels</span><span class="headingEndMark"> — </span>The additive value of monitoring the trend of anti-phospholipase A2 receptor (PLA2R) antibody levels during the three-to-six-month observation period remains uncertain, and there are insufficient data to guide the use of anti-PLA2R antibody levels in making initial treatment decisions. However, in our practice, we find that serum anti-PLA2R antibody levels measured by ELISA are valuable to inform initial treatment decisions when used in combination with clinical and laboratory parameters. A clinical case followed by four different anti-PLA2R antibody scenarios illustrates the range of decision making based upon the <strong>opinions</strong> of the authors and editors of this topic:</p><p class="bulletIndent1"><span class="glyph">●</span>A 60-year-old patient with newly diagnosed MN and nephrotic syndrome presents with proteinuria of 7 g/day, serum creatinine of 1.0 mg/dL (88 micromol/L), and serum albumin of 2.5 g/dL (measured by bromocresol purple methods) or 3.0 g/dL (measured by bromocresol green methods). Mild to moderate peripheral edema is present. The patient receives general supportive measures (including renin-angiotensin system inhibition) over a six-month observation period. Over the course of six months, proteinuria does not change appreciably (from 7 to 5 to 8 g/day), serum creatinine remains relatively stable (around 1.0 to 1.1 mg/dL [88.4 to 97 micromol/L]), and serum albumin remains stable (around 2.5 to 2.6 g/dL).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Settings where we would start immunosuppression:</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Anti-PLA2R antibody persistently high</strong> – At baseline, serum anti-PLA2R antibody level is 250 RU/mL. At three and six months, the anti-PLA2R antibody level is 275 and 250 RU/mL, respectively. In this scenario, we would initiate immunosuppressive therapy based upon the combination of persistent nephrotic syndrome and persistently high anti-PLA2R antibody levels.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Anti-PLA2R antibody increasing</strong> – At baseline, serum anti-PLA2R antibody level is 70 RU/mL. At three and six months, the anti-PLA2R antibody level increases to 130 and 200 RU/mL, respectively. In this scenario, we would initiate immunosuppressive therapy based upon the combination of persistent nephrotic syndrome and the progressively rising anti-PLA2R antibody titers.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Settings where we would treat expectantly:</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Anti-PLA2R antibody low and decreasing</strong> – At baseline, serum anti-PLA2R antibody level is 70 RU/mL. At three and six months, the anti-PLA2R antibody level decreases to 60 and 35 RU/mL, respectively. In this scenario, it would be reasonable to continue general supportive measures and defer starting immunosuppressive therapy. Although the patient has persistent nephrotic syndrome, kidney function remains stable, and progressively decreasing anti-PLA2R antibody levels suggest that the patient may achieve a spontaneous clinical remission.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Anti-PLA2R antibody high but decreasing</strong> – At baseline, serum anti-PLA2R antibody level is 250 RU/mL. At three and six months, the anti-PLA2R antibody level is 130 RU/mL and 80 RU/mL, respectively. In this scenario, we would not initiate immunosuppressive therapy but continue close, monthly monitoring.</p><p></p><p class="headingAnchor" id="H2738971649"><span class="h2">Choice of initial therapy based upon risk</span></p><p class="headingAnchor" id="H2138601893"><span class="h3">High or very high risk of progression</span><span class="headingEndMark"> — </span>In patients who are at high or very high risk of progression (see <a class="local">'Which patients need treatment'</a> above), we recommend treatment with immunosuppressive therapy and continued general supportive measures, rather than continued general supportive measures alone. As discussed above, patients at very high risk do not require a three-to-six-month observation period before immunosuppressive agents are initiated. (See <a class="local">'General measures in all patients'</a> above.)</p><p>The choice of immunosuppressive therapy depends upon how the patient is defined as high or very high risk:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients who are classified as high or very high risk because of abnormal or declining kidney function at presentation <strong>or </strong>rapidly declining kidney function due to MN, we suggest combination treatment with glucocorticoids and a cytotoxic agent (preferably <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>) rather than <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> or other therapies. Such patients have a higher urgency for initiating treatment, and cytotoxic therapy appears to provide the best protection against progressive kidney disease. We prefer cyclophosphamide, rather than <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a>, because it is associated with fewer adverse effects. In patients who wish to avoid cytotoxic therapy, treatment with rituximab may be a reasonable alternative. (See <a class="local">'Cytotoxic therapy plus glucocorticoids'</a> below and <a class="local">'Rituximab'</a> below.)</p><p></p><p class="bulletIndent1">In addition, patients with MN who experience a rapid decline in kidney function should be evaluated for other potential causes of worsening kidney function, such as crescentic glomerulonephritis (GN), acute hypersensitivity interstitial nephritis, or acute bilateral renal vein thrombosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who are classified as high or very high risk and have stable kidney function, we suggest treatment with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> rather than cytotoxic therapy or other therapies. Such patients have a lower urgency for initiating treatment than those with progressive kidney failure, and rituximab, which has less treatment-related toxicity, may be preferable. We prefer rituximab to a calcineurin inhibitor (CNI; <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>) because of the more prolonged remission with rituximab and higher relapse rate of CNIs after therapy has been discontinued. However, either a CNI or combination therapy with glucocorticoids plus a cytotoxic agent is a reasonable alternative to rituximab in patients who are anti-PLA2R antibody negative [<a href="#rid37">37</a>]. (See <a class="local">'Rituximab'</a> below and <a class="local">'Calcineurin inhibitors'</a> below and <a class="local">'Cytotoxic therapy plus glucocorticoids'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We do <strong>not</strong> give glucocorticoids alone to high-risk patients, as this has not been shown to be effective.</p><p></p><p>The rationale for our approach in high-risk patients is based primarily upon the results of the Membranous Nephropathy Trial of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> (MENTOR) and the United Kingdom Membranous Trial [<a href="#rid37">37,38</a>]. In the MENTOR trial, which included patients with primary MN who had heavy proteinuria but mostly preserved kidney function, treatment with rituximab was more effective than <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> at maintaining complete or partial remission of proteinuria at 24 months [<a href="#rid37">37</a>]. The United Kingdom Membranous Trial, which specifically enrolled patients with primary MN who had deteriorating kidney function, found that the combination of glucocorticoids and cytotoxic therapy was superior to cyclosporine and to supportive therapy alone at preventing further loss of kidney function and end-stage kidney disease (ESKD) [<a href="#rid38">38</a>]. Additional data supporting our approach come from randomized trials in moderate-risk patients that found that cytotoxic therapy plus glucocorticoids prevented long-term progression to ESKD compared with supportive therapy alone (see <a class="local">'Moderate risk of progression'</a> below). There are no randomized trials that have directly compared rituximab with cytotoxic therapy in high-risk patients with primary MN.</p><p class="bulletIndent1"><span class="glyph">●</span>In the open-label, multicenter MENTOR trial, 130 patients with proteinuria ≥5 g/day and 24-hour creatinine clearance ≥40 mL/min/1.73 m<sup>2</sup> after at least three months of supportive care (angiotensin inhibition, blood pressure control, dietary sodium and protein restriction) were randomly assigned to <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (two infusions of 1 g administered 14 days apart; repeated at six months in case of partial response) or oral <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (3.5 mg/kg per day for six months [or 12 months in case of partial response at six months], with dose adjustment to maintain a 12-hour trough concentration of 125 to 175 ng/mL) [<a href="#rid37">37</a>]. At baseline, median proteinuria was 8.9 g/day and median serum albumin was 2.5 g/dL in both treatment arms; median creatinine clearance was 84.9 to 87.4 mL/min/1.73 m<sup>2</sup>. Seventy-four percent of patients were anti-PLA2R antibody positive, and median anti-PLA2R antibody levels at baseline were similar between the two groups. The primary endpoint was a composite of complete (proteinuria &lt;0.3 g/day and serum albumin ≥3.5 g/dL) or partial (reduction in proteinuria of ≥50 percent and final proteinuria between 0.3 and 3.5 g/day) remission at 24 months. The following results were noted:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At 12 months, rates of complete or partial remission were similar between the two groups (60 and 52 percent for <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, respectively). However, at 24 months, patients receiving rituximab had a higher rate of complete or partial remission than those receiving cyclosporine (60 versus 20 percent, respectively); only patients receiving rituximab achieved complete remission (35 versus 0 percent in the cyclosporine group).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among the patients who achieved complete or partial remission at 24 months, the mean creatinine clearance was higher in the <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> group than in the <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> group (96 versus 72 mL/min/1.73 m<sup>2</sup> at 12 months and 100 versus 87 mL/min/1.73 m<sup>2</sup> at 24 months, respectively).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among anti-PLA2R antibody-positive patients who achieved complete or partial remission at 24 months, those who received <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> had a greater, more rapid, and more sustained decrease in anti-PLA2R antibody levels than those who received <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who did not respond to <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> had higher anti-PLA2R antibody levels at baseline compared with those who achieved a partial or complete remission with rituximab.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among anti-PLA2R antibody-negative patients, rates of complete or partial remission at 12 months were comparable with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (67 versus 68 percent, respectively).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serious adverse events occurred in 17 percent of patients receiving <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and 31 percent of those receiving <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, although this difference was not statistically significant.</p><p></p><p class="bulletIndent1">These findings show that <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> is more effective than <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> at maintaining clinical remission and may be better tolerated. However, patients in both study arms with high anti-PLA2R antibody titers at baseline may be less responsive to therapy, and it has been suggested, at least for rituximab, that patients might benefit from additional treatments [<a href="#rid39">39</a>] or an alternative treatment strategy to achieve remission. Since a placebo control group was not included in this trial, rates of remission with treatment cannot be formally compared with the rate of spontaneous remission. Longer-term follow-up data are needed to determine rates of relapse among rituximab-treated patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The United Kingdom membranous trial randomly assigned 108 patients with a baseline serum creatinine less than 3.4 mg/dL (300 micromol/L) and at least a 20 percent decline in eGFR during the preceding two years to one of three therapies: supportive treatment plus alternating cycles of glucocorticoids and oral <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a> for six months, supportive treatment plus <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> for 12 months, or supportive treatment alone [<a href="#rid38">38</a>]. Rates of the primary endpoint (an additional decline in eGFR of at least 20 percent) were lower with glucocorticoids/chlorambucil as compared with supportive treatment alone (58 versus 84 percent). In addition, cyclosporine did not reduce the incidence of kidney function loss as compared with supportive treatment (81 versus 84 percent). Fewer patients who received glucocorticoids/chlorambucil developed ESKD (one patient compared with four patients receiving supportive treatment and six patients receiving cyclosporine). The frequency of adverse events was similar in the glucocorticoid/chlorambucil and cyclosporine groups, although patients receiving glucocorticoids/chlorambucil had more serious adverse events than those receiving supportive treatment only (primarily hematological events such as leukopenia and anemia).</p><p></p><p class="bulletIndent1">Although the United Kingdom Membranous Trial used <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a>, a cyclophosphamide-based regimen is thought to be equally effective and less toxic, as noted in a randomized head-to-head comparative trial that primarily enrolled moderate-risk patients (mean protein excretion 7 to 8 g/day and mean serum creatinine 1.05 mg/dL [93 micromol/L]) [<a href="#rid40">40</a>]. Chlorambucil also has more side effects; therefore, we prefer administering a cyclophosphamide-based regimen. (See  <a class="medical medical_review" href="/z/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases"</a>.)</p><p></p><p class="headingAnchor" id="H2666348261"><span class="h3">Moderate risk of progression</span><span class="headingEndMark"> — </span>Our approach to initial therapy in patients at moderate risk of progression varies depending upon the course of disease during an initial three-to-six-month observation period with maximal general supportive measures (see <a class="local">'Which patients need treatment'</a> above and <a class="local">'General measures in all patients'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>In moderate-risk patients who show a progressive increase in proteinuria over the observation period, we recommend treatment with immunosuppressive therapy and continued general supportive measures, rather than continued general supportive measures alone. (See <a class="local">'General measures in all patients'</a> above and <a class="local">'Clinical utility of anti-PLA2R antibody levels'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In moderate-risk patients who show stable proteinuria over the observation period, we suggest immunosuppressive therapy and continued general supportive measures, rather than continued general supportive measures alone. However, some clinicians would continue to withhold immunosuppressive therapy beyond six months in such patients if they are doing well, especially if serum albumin is increasing, anti-PLA2R antibody levels (if initially positive) are low or decreasing, or if the patients are at high risk of having an adverse event with immunosuppressive therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In moderate-risk patients who show a progressive decline in proteinuria over the observation period, we withhold immunosuppression and continue general supportive measures.</p><p></p><p>Preferred first-line immunosuppressive therapies for moderate-risk patients with primary MN include <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, combination therapy with glucocorticoids plus a cytotoxic agent (preferably <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>), or a CNI (<a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>). The choice among these regimens depends upon several factors, including clinician and patient preference, drug availability and cost, efficacy, toxicity, and tolerability:</p><p class="bulletIndent1"><span class="glyph">●</span>In most moderate-risk patients who require immunosuppressive therapy, we suggest <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> rather than glucocorticoids plus cytotoxic therapy or a CNI. (See <a class="local">'Rituximab'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> is unavailable, <strong>either</strong> combination therapy with glucocorticoids plus a cytotoxic agent <strong>or</strong> CNI monotherapy is a reasonable alternative. Some experts prefer cytotoxic therapy in moderate-risk patients with evidence of disease progression (eg, decreasing eGFR, increasing proteinuria, or decreasing serum albumin), given the higher relapse rates and potential for nephrotoxicity with CNIs [<a href="#rid41">41-43</a>]. In patients with more stable disease, however, some experts prefer CNIs over cytotoxic therapy given their comparable short-term efficacy and better overall safety profile. If cytotoxic therapy is chosen, we prefer <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> over <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a> since chlorambucil has more side effects. If a CNI is selected, either <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> is a reasonable choice. (See <a class="local">'Cytotoxic therapy plus glucocorticoids'</a> below and <a class="local">'Calcineurin inhibitors'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We do <strong>not</strong> routinely use <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF), natural adrenocorticotropic hormone (ACTH) gel, or synthetic ACTH as initial therapy in moderate-risk patients. However, such agents may be considered in patients who do not respond to all of the first-line therapies. (See <a class="local">'Treatment of resistant disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We do <strong>not</strong> give glucocorticoids alone to moderate-risk patients, as this has not been shown to be effective.</p><p></p><p>Our preference for <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> is based upon several studies demonstrating its efficacy and safety as initial therapy and as therapy for patients who have not responded to previous treatment with CNIs [<a href="#rid37">37,44-54</a>]. Although there have been no large, randomized trials directly comparing rituximab with cytotoxic therapy in patients with MN, we prefer rituximab to cytotoxic therapy based upon data from other trials and observational studies that suggest comparable short-term outcomes (60 to 70 percent remission rates) and a better safety profile with rituximab [<a href="#rid37">37,44-54</a>]. We prefer rituximab to a CNI based upon data from the MENTOR trial (which included patients who would be classified as moderate or high risk (see <a class="local">'High or very high risk of progression'</a> above)) that suggested that rituximab was more effective than <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> at sustaining complete or partial remission of proteinuria beyond the 12 months of active treatment and had better patient adherence to therapy [<a href="#rid37">37</a>]. However, certain moderate-risk patients with higher serum anti-PLA2R antibody levels (eg, ≥150 to 200 RU/mL) [<a href="#rid37">37,48</a>] may require additional treatments with rituximab or an alternative regimen (such as combination therapy with glucocorticoids and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>) to achieve remission [<a href="#rid39">39</a>]. (See <a class="local">'Rituximab'</a> below.)</p><p>Several randomized trials have demonstrated the benefit of immunosuppressive therapy compared with supportive therapy alone in patients with primary MN who would be classified as having moderate risk for progression:</p><p class="bulletIndent1"><span class="glyph">●</span>In the Evaluate <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> Treatment for Idiopathic Membranous Nephropathy (GEMRITUX) trial, 75 patients with persistent proteinuria greater than 3.5 g/day after six months of treatment with angiotensin inhibition, diuretics, and a statin (general supportive measures) were randomly assigned to rituximab (two infusions of 375 mg/m<sup>2</sup> administered one week apart) or no rituximab [<a href="#rid44">44</a>]. General supportive measures were continued in all patients. At six months, there was no significant difference in the primary composite endpoint of complete or partial remission of proteinuria between patients treated with or without rituximab. Proteinuria, serum creatinine, and eGFR at six months were also similar between the two groups, but serum albumin levels were higher in those treated with rituximab (3.0 versus 2.4 g/dL). Anti-PLA2R antibodies, which were present in 73 percent of patients at baseline, disappeared in a greater proportion receiving rituximab (50 versus 12 percent). Serious adverse events were similar between the two groups.</p><p></p><p class="bulletIndent1">The lack of benefit on proteinuria reduction from <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> at six months may be attributed in part to the short duration to the preset primary endpoint. In a posttrial observational phase that followed patients for an additional 12 months, the rate of complete or partial remission was higher among patients treated with rituximab (65 versus 34 percent) [<a href="#rid44">44</a>]. In addition, patients treated with rituximab had less proteinuria (2195 versus 4701 mg/g) and higher serum albumin levels (3.2 versus 2.7 g/dL). These findings are consistent with observational studies that demonstrate a maximal reduction in proteinuria at 18 to 24 months after treatment with rituximab [<a href="#rid45">45,55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Three randomized trials found that <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a>, both given with glucocorticoids, are effective in inducing remission of proteinuria [<a href="#rid5">5,6,40</a>]. Two of the trials, mostly of patients with moderate disease (mean proteinuria 6 g/day in one), reported 10-year follow-up and showed that cytotoxic therapy also prevented progression to ESKD [<a href="#rid5">5,6</a>]. The patients receiving immunosuppressive therapy had significantly higher rates of complete or partial remission (88 versus 47 percent and 72 versus 34 percent with symptomatic therapy alone) and a higher rate of surviving without ESKD (92 versus 60 percent and 89 versus 65 percent).</p><p></p><p class="bulletIndent1">Cyclophosphamide- and chlorambucil-based regimens are equally effective, as noted in a randomized head-to-head comparative trial that primarily enrolled moderate-risk patients [<a href="#rid40">40</a>]. However, since <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a> has more side effects, we prefer administering the cyclophosphamide-based regimen. Most studies evaluating cytotoxic therapy have included <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, and it is the clinical impression of many clinicians that <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> alone is likely to be less beneficial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Both <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> have been shown in randomized trials to be effective in lowering proteinuria in moderate-risk patients with primary MN [<a href="#rid56">56,57</a>]. The best data are from a randomized trial of 51 patients (mean proteinuria 9.3 g/day and mean creatinine 1.2 mg/dL [106 micromol/L]) who were unresponsive to at least an eight-week course of daily glucocorticoid therapy [<a href="#rid56">56</a>]. The patients were assigned to <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (0.15 mg/kg up to a maximum dose of 15 mg/day) plus either placebo or cyclosporine (dose adjusted to maintain trough blood level of 125 to 225 microgram/L) for 26 weeks. The cyclosporine-treated group had a significantly higher rate of complete (≤300 mg/day) or partial (&lt;3.5 g/day plus a ≥50 percent reduction from baseline) remission of proteinuria. Kidney function was the same in both groups. One year after the cessation of therapy, relapse of proteinuria was common, but 39 percent of treated patients were still in remission, compared with 13 percent with placebo.</p><p></p><p class="bulletIndent1">The efficacy of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> (without glucocorticoids) was demonstrated in a randomized trial of 48 patients with MN who were treated with tacrolimus (0.05 mg/kg per day for 12 months with a six-month taper) or placebo [<a href="#rid57">57</a>]. The rate of complete or partial remission was significantly higher with tacrolimus at both 12 months (82 versus 24 percent) and 18 months (94 versus 35 percent). However, almost one-half of the patients who were in remission by the 18<sup>th</sup> month developed a relapse of nephrotic syndrome after tacrolimus withdrawal.</p><p></p><p>There have been several trials and meta-analyses comparing the efficacy of different immunosuppressive regimens in moderate-risk patients with primary MN. Most trials have compared a CNI-based regimen with cytotoxic therapy and have found comparable rates of short-term remission but higher rates of relapse with CNIs after treatment withdrawal [<a href="#rid41">41,58-61</a>]. There are no large trials that have directly compared <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> alone with cytotoxic therapy. One small pilot trial comparing rituximab with cyclical <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> and glucocorticoids in moderate-risk patients suggested comparable rates of complete or partial remission at 24 months and similar rates of short-term adverse events [<a href="#rid54">54</a>]. Another randomized trial (Sequential Treatment with <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> and Rituximab versus Alternating Corticosteroids and Cyclophosphamide in PMN study [STARMEN]) that compared cyclical cytotoxic therapy with the combination of a CNI plus a single dose of rituximab at six months reported a higher rate of complete or partial remission of nephrotic syndrome at 24 months with cytotoxic therapy [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H1514111540"><span class="h3">Low risk of progression</span><span class="headingEndMark"> — </span>In patients at low risk of progression (see <a class="local">'Which patients need treatment'</a> above), we recommend continued observation with general supportive measures rather than administering immunosuppressive therapy. Such patients generally have excellent long-term prognosis and often undergo spontaneous partial or complete remission [<a href="#rid4">4-6,8</a>]. (See <a class="local">'General measures in all patients'</a> above.)</p><p>Low-risk patients should be monitored periodically for disease progression that might warrant therapy. We suggest clinical assessment, measurement of serum creatinine and 24-hour urine protein excretion, and measurement of anti-PLA2R antibody levels every three months for two years and twice yearly thereafter since the risk of developing progressive disease falls significantly after two years. The rationale for prolonged monitoring for disease progression was provided by a review of 395 patients with MN, 108 of whom (27 percent) presented with subnephrotic proteinuria [<a href="#rid8">8</a>]. Among these patients, 66 (61 percent) progressed to nephrotic syndrome; of these, 46 patients (70 percent) progressed within the first year, 11 (18 percent) progressed between years 1 to 4, and 9 patients (13 percent) progressed after year 4 (19 percent). (See <a class="local">'Monitoring and modifying therapy'</a> below.)</p><p class="headingAnchor" id="H309686340"><span class="h2">Dosing, duration, and toxicity of first-line therapies</span></p><p class="headingAnchor" id="H2138528729"><span class="h3">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> is an anti-CD20 monoclonal antibody that depletes CD20-positive B cells. Rituximab is the preferred first-line immunosuppressive therapy for high- or very-high-risk patients who have normal or near-normal kidney function and moderate-risk patients. (See <a class="local">'High or very high risk of progression'</a> above and <a class="local">'Moderate risk of progression'</a> above.)</p><p>The optimal dosing regimen for <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> is uncertain. We administer rituximab using the dose that was given in the MENTOR trial [<a href="#rid37">37</a>], specifically 1 g initially followed 14 days later by another 1 g dose. Some experts use an alternative regimen, administering 375 mg/m<sup>2</sup> weekly for four weeks or a B cell-driven approach [<a href="#rid50">50</a>] in which a second dose of 375 mg/m<sup>2</sup> is given if ≥5 circulating B cells/microL are detected by flow cytometry one week after treatment. The rationale for two additional doses is to induce a more profound B cell depletion. However, there are no controlled trials that have compared the efficacy of the various rituximab regimens.</p><p>In patients treated with an initial dose of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> of 2 g, we do not routinely check peripheral B cell counts. However, in centers that are used to administering lower doses (eg, 375 mg/m<sup>2</sup>, one or two doses), we suggest checking peripheral blood B lymphocyte counts (by monitoring CD19-positive cells) one week after the last rituximab dose to ascertain B cell depletion. We administer an additional dose of rituximab (1 g) if B cell depletion is not complete.</p><p><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> is generally well tolerated. Short-term adverse events include infusion reactions, serum sickness, hypogammaglobulinemia, opportunistic infections, and, rarely, anaphylaxis. The adverse effects of rituximab are discussed in more detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Rituximab'</a>.)</p><p></p><p class="headingAnchor" id="H415746716"><span class="h3">Cytotoxic therapy plus glucocorticoids</span><span class="headingEndMark"> — </span>Combination therapy with a cytotoxic agent (<a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> or <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a>) and glucocorticoids is the preferred initial therapy for patients classified as high or very high risk because of deteriorating kidney function due to MN and for whom immunosuppressive therapy is felt to be appropriate. In addition, cytotoxic therapy can be used as initial therapy in patients at moderate risk of progression if <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> is unavailable. (See <a class="local">'High or very high risk of progression'</a> above and <a class="local">'Moderate risk of progression'</a> above.)</p><p>We prefer <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> since <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a> has more side effects. An acceptable regimen is the "modified Ponticelli" regimen [<a href="#rid6">6,40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>During months 1, 3, and 5, treat with intravenous (IV) <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (1 g/day for three days), followed by oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (0.5 mg/kg per day for 28 days). At the end of months 1, 3, and 5, oral prednisone can generally be discontinued without a taper.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During months 2, 4, and 6, treat with oral <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (2 mg/kg per day, maximum daily dose of 200 mg). We typically reduce the dose by 25 percent in older adults (age &gt;75 years) and adjust the dose appropriately in patients with impaired kidney function  (<a class="graphic graphic_table graphicRef60883" href="/z/d/graphic/60883.html" rel="external">table 2</a>). We titrate the dose to achieve a peripheral blood lymphocyte count of &lt;700 cells/microL and a white blood cell count &gt;3500 cells/microL.</p><p></p><p>Some centers may prefer daily (rather than cyclical) <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> at a dose of 1.5 mg/kg per day combined with daily oral glucocorticoids (<a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or equivalent 0.25 mg/kg per day or 0.5 mg/kg every other day). In patients receiving daily cyclophosphamide, we limit the maximum cumulative dose to 25 g, given the increased risk of malignancy with longer duration of therapy. There are insufficient data to advocate the use of IV cyclophosphamide. Upon completion of six months of cyclophosphamide and glucocorticoids, we taper the glucocorticoids over a period of eight weeks.</p><p>In patients who are planning to conceive, we suggest avoidance of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>. If cyclophosphamide is the only option, we suggest a maximum cumulative dose of 10 g. Patients must be clearly informed of the significant risk for infertility and should be referred to a fertility clinic to discuss egg/sperm harvesting. (See  <a class="medical medical_review" href="/z/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases", section on 'Malignancy'</a> and  <a class="medical medical_review" href="/z/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases", section on 'Gonadal toxicity'</a>.)</p><p>The use of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> and glucocorticoids is associated with significant toxicity. Earlier trials may have underreported rates of serious adverse events associated with cyclical immunosuppression therapies [<a href="#rid5">5,6,62</a>]. A subsequent study clearly demonstrated the significant toxicity associated with daily glucocorticoid/cyclophosphamide regimens, even among patients treated with lower doses (1.5 mg/kg per day of cyclophosphamide) [<a href="#rid63">63</a>]. A more detailed discussion of the toxicities of cyclophosphamide and glucocorticoids is presented elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p></p><p class="headingAnchor" id="H3599047587"><span class="h3">Calcineurin inhibitors</span><span class="headingEndMark"> — </span>Both <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> have proven short-term efficacy in patients with primary MN and can be used as immunosuppressive therapy in moderate-risk patients if <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> is unavailable and the patient wishes to avoid cytotoxic therapy. (See <a class="local">'Moderate risk of progression'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>If a cyclosporine-based approach is chosen, the preferred regimen is treatment for at least six months at a dose of 3 to 5 mg/kg per day in two divided doses to maintain whole blood trough levels of 120 to 200 ng/mL; some clinicians would also initiate therapy with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> given every other day (maximum 10 mg every other day).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a tacrolimus-based approach is chosen, the preferred regimen is 0.05 to 0.1 mg/kg per day for at least six months in two divided doses to maintain whole blood trough levels between 3 and 5 ng/mL. The dose may be increased to achieve a higher trough level between 5 and 8 ng/mL if there is no reduction in proteinuria by two months, provided that kidney function has not worsened.</p><p></p><p>Among patients who attain at least a partial remission (protein excretion &lt;3.5 g/day plus a ≥50 percent reduction from baseline), we continue the dose of the CNI for an additional six months. In patients on <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, we then reduce the dose to 1.5 to 2.5 mg/kg per day to minimize the risk of nephrotoxicity and administer this dose for at least one to two years. In patients on <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, we reduce the dose by 25 to 50 percent over the same time frame as with cyclosporine. The duration of therapy is based upon an ongoing assessment of the benefits and risks. Some clinicians may choose to withdraw therapy earlier and more rapidly in patients who achieve a disappearance of anti-PLA2R antibodies or a complete clinical remission (protein excretion ≤300 mg/day). Conversely, some clinicians may choose to continue the CNI indefinitely if achieving remission was difficult, provided that there are no signs of nephrotoxicity. Relapse of proteinuria can occur after the CNI is discontinued. (See <a class="local">'Treatment of relapsing disease'</a> below.)</p><p>In general, patients who do not respond to one of these CNIs are unlikely to respond to the other.</p><p>The adverse effects of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, including their potential nephrotoxicity, are discussed in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity"</a>.)</p><p></p><p class="headingAnchor" id="H1574860326"><span class="h2">Monitoring and modifying therapy</span><span class="headingEndMark"> — </span>All patients who are receiving treatment for primary MN should be closely monitored for clinical response to therapy. In patients with PLA2R-associated primary MN, serial assessment of anti-PLA2R antibody levels may be useful for monitoring the immunologic activity of disease and guiding treatment decisions.</p><p class="headingAnchor" id="H2940946125"><span class="h3">Goals of therapy</span><span class="headingEndMark"> — </span>In patients with primary MN who are receiving immunosuppressive therapy, the goals of therapy are to induce a clinical remission and, in those who have positive serum anti-PLA2R antibodies, to achieve an immunologic remission. We use the following definitions of clinical and immunologic response:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical response</strong> – Clinical response in patients with MN is reported in terms of degree of reduction in proteinuria. We use the following definitions:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A complete clinical remission is a reduction in proteinuria to ≤300 mg/day</p><p class="bulletIndent2"><span class="glyph">•</span>A partial clinical remission in patients presenting with nephrotic-range proteinuria is a reduction in proteinuria of ≥50 percent from baseline and to &gt;300 mg/day and &lt;3.5 g/day</p><p class="bulletIndent2"><span class="glyph">•</span>No clinical remission is a less than 50 percent reduction in proteinuria from baseline or proteinuria ≥3.5 g/day</p><p></p><p class="bulletIndent1">Most patients with primary MN who successfully achieve a clinical remission will demonstrate a reduction in proteinuria within 6 to 24 months of immunosuppressive therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunologic response</strong> – In patients with PLA2R-associated primary MN, serial assessment of serum anti-PLA2R antibody levels can be used to monitor the immunologic activity of the disease. Immunologic remission is defined as depletion of anti-PLA2R antibodies, as evidenced by anti-PLA2R antibody titers below the cut-off value for a positive result (&lt;14 RU/mL by ELISA, although some experts prefer to use a lower cut-off of &lt;2 RU/mL to define true absence of anti-PLA2R antibody) and/or a negative indirect immunofluorescence test.</p><p></p><p class="bulletIndent1">A decline in anti-PLA2R antibody levels may predict the clinical response to treatment. Several studies have shown that a decrease in anti-PLA2R antibody levels consistently precedes a decrease in proteinuria  (<a class="graphic graphic_figure graphicRef114639" href="/z/d/graphic/114639.html" rel="external">figure 1</a>) [<a href="#rid23">23,26,48,64-68</a>]. Among patients who achieve an immunologic remission, a remission in proteinuria usually follows within 12 to 24 months. Clinicians should be aware of this characteristic delay between immunologic and clinical remission and should not necessarily modify the treatment plan if the patient has achieved an immunologic remission but has not yet experienced a significant reduction in proteinuria.</p><p></p><p class="bulletIndent1">Some [<a href="#rid2">2,37,67,68</a>], but not all [<a href="#rid23">23,26,64</a>], studies have shown that the rate of reduction in anti-PLA2R antibody levels may depend upon the type of immunosuppressive therapy given.</p><p></p><p class="bulletIndent1">Anti-PLA2R antibody levels at the completion of therapy may predict long-term treatment outcomes. In one study, patients with undetectable antibody levels after treatment were more likely to remain in remission at five years than those with detectable antibodies (58 versus 0 percent, respectively) [<a href="#rid67">67</a>]. (See <a class="local">'Prognosis'</a> below.)</p><p></p><p class="bulletIndent1">A re-emergence of or an increase in anti-PLA2R antibody levels in a patient who previously achieved clinical remission may predict clinical relapse [<a href="#rid48">48</a>]. (See <a class="local">'Treatment of relapsing disease'</a> below.)</p><p></p><p class="headingAnchor" id="H1966077859"><span class="h3">Non-PLA2R-associated MN</span><span class="headingEndMark"> — </span>In patients with non-PLA2R-associated primary MN (see <a class="local">'Terminology'</a> above), we perform a clinical assessment and measure serum creatinine, serum albumin, and 24-hour urine protein excretion every two to three months. Based upon these parameters, we determine the clinical response to treatment after <strong>six months</strong> of therapy and modify treatment and monitoring as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with complete clinical remission </strong>– In patients who achieve a complete clinical remission (see <a class="local">'Goals of therapy'</a> above) at six months, we reduce or discontinue therapy depending upon the agent(s) being used. If the patient was treated with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, we do not administer any additional doses of rituximab. If the patient was treated with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> plus glucocorticoids, we discontinue these agents. If the patient was treated with a CNI, we start tapering and withdraw the agent after three to six months. In all patients, we continue general supportive measures until complete clinical remission has been maintained for 6 to 12 months (see <a class="local">'General measures in all patients'</a> above). We reduce the frequency of laboratory monitoring to every three to six months for the first year after remission and then every 6 to 12 months thereafter. The frequency of monitoring should increase if the patient shows signs of increasing proteinuria, decreasing serum albumin, or increasing serum creatinine; such patients should be evaluated for disease relapse. (See <a class="local">'Treatment of relapsing disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without complete clinical remission </strong>– In patients who do <strong>not</strong> achieve a complete clinical remission at six months, we take the following approach:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who have unchanged or increasing proteinuria with no increase in serum albumin <strong>or </strong>who have a ≥25 percent reduction in eGFR are considered to have an <strong>unsatisfactory</strong> initial response to therapy. In such patients, we modify the treatment regimen depending upon the agent(s) being used. If the patient was treated with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, we would switch to combination therapy with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> plus glucocorticoids. If the patient was treated with cyclophosphamide plus glucocorticoids, we add rituximab (two infusions of 1 g administered 14 days apart). If the patient was treated with a CNI, we switch to rituximab or cyclophosphamide plus glucocorticoids.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who have decreasing proteinuria (≥25 percent reduction) <strong>and</strong> stable (&lt;25 percent reduction) eGFR are considered to have a <strong>satisfactory</strong> initial response to therapy. However, because it remains uncertain if such patients will achieve a partial or complete clinical remission, we continue or modify immunosuppressive therapy depending upon the agent(s) being used. If the patient was treated with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, we give an additional course of rituximab (two infusions of 1 g administered 14 days apart) [<a href="#rid37">37</a>]. If the patient was treated with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> plus glucocorticoids, we discontinue these agents to reduce the risk of toxicity and continue monitoring since it can take at least 12 to 18 months to achieve a clinical remission. If the patient was treated with a CNI, we continue the same dose for another six months after the proteinuria nadir has been achieved and then begin to reduce the dose, as described elsewhere in this topic. (See <a class="local">'Calcineurin inhibitors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We continue general supportive measures until complete remission has been achieved and maintained for 6 to 12 months (see <a class="local">'General measures in all patients'</a> above). We continue to perform a clinical assessment and laboratory monitoring every two to three months and reevaluate the patient's response after six months (ie, a total of 12 months of therapy).</p><p></p><p>Patients who do not achieve a reduction in proteinuria after treatment with rituximab-, cyclophosphamide-, or CNI-based regimens are considered to have resistant disease. The management of such patients is discussed below. (See <a class="local">'Treatment of resistant disease'</a> below.)</p><p class="headingAnchor" id="H4118617339"><span class="h3">PLA2R-associated MN</span><span class="headingEndMark"> — </span>In patients with PLA2R-associated primary MN (see <a class="local">'Terminology'</a> above) who are receiving treatment, we perform a clinical assessment and measure serum creatinine, serum albumin, 24-hour urine protein excretion, and serum anti-PLA2R antibody levels every two to three months. Based upon these parameters, we determine both the clinical and immunologic response to treatment after <strong>six months</strong> of therapy and modify treatment and monitoring as follows  (<a class="graphic graphic_algorithm graphicRef127044" href="/z/d/graphic/127044.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with immunologic remission </strong>– In patients who achieve an immunologic remission (see <a class="local">'Goals of therapy'</a> above) at six months, we reduce or discontinue therapy depending upon the agent(s) being used. If the patient was treated with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, we do not administer any additional doses of rituximab. If the patient was treated with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> plus glucocorticoids, we discontinue these agents [<a href="#rid69">69</a>]. If the patient was treated with a CNI, we start tapering and withdraw the agent after three to six months. In all patients, we continue general supportive measures until complete clinical remission has been achieved and maintained for 6 to 12 months (see <a class="local">'General measures in all patients'</a> above). We reduce the frequency of laboratory monitoring to every three to six months for the first year after immunologic remission and then every 6 to 12 months thereafter. The frequency of monitoring should increase if the patient shows signs of increasing proteinuria, decreasing serum albumin, increasing serum creatinine, or increasing anti-PLA2R antibody levels; such patients should be evaluated for disease relapse. (See <a class="local">'Treatment of relapsing disease'</a> below.)</p><p></p><p class="bulletIndent1">In most patients who achieve an immunologic remission, a clinical remission in proteinuria usually follows within 12 to 24 months. Some patients who achieve an immunologic remission may not achieve a complete clinical remission within this time frame. This can be caused by incomplete remodeling of the glomerular filtration barrier (in which case proteinuria may eventually decrease further) or due to irreversible chronic damage (in which case some degree of proteinuria may persist), and additional immunosuppressive therapy is not warranted in these patients. Patients who achieve an immunologic remission at six months but have increasing proteinuria or decreasing eGFR are uncommon and should be evaluated for other causes of worsening kidney function and/or worsening proteinuria (eg, renal vein thrombosis). In such patients, serum anti-PLA2R antibody testing should also be repeated to confirm that immunologic remission has been maintained.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without immunologic remission </strong>– In patients who do <strong>not</strong> achieve an immunologic remission at six months, we take the following approach:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who have unchanged or increasing serum anti-PLA2R antibody levels, unchanged or increasing proteinuria (with no increase in serum albumin), <strong>or</strong> a ≥25 percent reduction in eGFR are considered to have an unsatisfactory initial response to therapy. In such patients, we modify the treatment regimen depending upon the agent(s) being used. If the patient was treated with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, we would switch to combination therapy with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> plus glucocorticoids. If the patient was treated with cyclophosphamide plus glucocorticoids, we add rituximab (two infusions of 1 g administered 14 days apart). If the patient was treated with a CNI, we switch to rituximab or cyclophosphamide plus glucocorticoids.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who have decreasing anti-PLA2R antibody levels, decreasing proteinuria, <strong>and</strong> stable (&lt;25 percent reduction) eGFR are considered to have a satisfactory initial response to therapy. However, because it remains uncertain if such patients will achieve a clinical remission, we continue or modify immunosuppressive therapy depending upon the agent(s) being used. If the patient was treated with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, we give an additional course of rituximab (two infusions of 1 g administered 14 days apart) [<a href="#rid37">37</a>]. If the patient was treated with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> plus glucocorticoids, we discontinue these agents to reduce the risk of toxicity and continue monitoring since it can take at least 12 to 18 months to achieve a clinical remission. Some authors would switch to <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (1000 mg twice daily) for up to six months [<a href="#rid69">69</a>]. If the patient was treated with a CNI, we switch to rituximab; if rituximab is not available, we treat with cyclophosphamide plus glucocorticoids.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We continue general supportive measures until complete remission has been achieved and maintained for 6 to 12 months (see <a class="local">'General measures in all patients'</a> above). We continue to perform a clinical assessment and laboratory monitoring every two to three months and reevaluate the patient's response after six months (ie, a total of 12 months of therapy).</p><p></p><p>Patients who do not achieve a clinical or immunologic remission after treatment with rituximab-, cyclophosphamide-,<strong> and</strong> CNI-based regimens are considered to have resistant disease. The management of such patients is discussed below. (See <a class="local">'Treatment of resistant disease'</a> below.)</p><p class="headingAnchor" id="H911507134"><span class="h1">TREATMENT OF RELAPSING DISEASE</span><span class="headingEndMark"> — </span>In patients with primary MN, a relapse is a return of proteinuria to ≥3.5 g/day after an initial complete or partial response to immunosuppressive therapy. Patients with a relapse after an initial partial remission should also have a ≥50 percent increase in proteinuria from the proteinuria nadir in addition to proteinuria ≥3.5 g/day. Approximately one-third of patients who respond to immunosuppressive therapy eventually develop a relapse [<a href="#rid6">6,40,70-72</a>], which may adversely affect their long-term prognosis [<a href="#rid73">73,74</a>]. Relapse rates are higher in patients who achieve partial remission than in patients who achieve complete remission (approximately 50 versus 25 percent) [<a href="#rid75">75,76</a>]. Among patients with partial remission, the risk of relapse is higher in those who remain hypoalbuminemic compared with those who have normal serum albumin levels.</p><p>Relapses are mostly caused by activity of the MN, as is illustrated by the reappearance of anti-phospholipase A2 receptor (PLA2R) antibodies in patients with PLA2R-associated MN. In rare instances, a repeat kidney biopsy may be needed to ascertain the cause of relapsing proteinuria.</p><p>Relapsing disease may require repeat treatment with immunosuppressive therapy. However, some patients with relapsing disease may develop a spontaneous remission without additional treatment, even if they previously received immunosuppressive therapy for their initial presentation. Thus, in patients who develop a relapse, we suggest a six-month observation period with general supportive measures to reassess the risk for progressive disease, using the same approach as that for newly diagnosed patients with primary MN. (See <a class="local">'Which patients need treatment'</a> above.)</p><p>In patients who require immunosuppressive therapy, the choice of agent for relapse depends upon the initial immunosuppressive regimen:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients who were initially treated with cytotoxic therapy plus glucocorticoids, we treat with either <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> or a calcineurin inhibitor (CNI). Given the significant toxicity associated with cytotoxic therapy and glucocorticoids, we <strong>avoid</strong> using this regimen for relapse unless the patient cannot receive rituximab or a CNI. (See <a class="local">'Rituximab'</a> above and <a class="local">'Calcineurin inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who were initially treated with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> or a CNI and have stable kidney function, we typically retreat with the same agent and regimen that was used to achieve the prior clinical response. In those who are experiencing a deterioration in kidney function, we prefer to use cytotoxic therapy (<a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>) plus glucocorticoids. (See <a class="local">'Rituximab'</a> above and <a class="local">'Calcineurin inhibitors'</a> above and <a class="local">'Cytotoxic therapy plus glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who do not tolerate or cannot receive <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, a CNI, or cytotoxic therapy plus glucocorticoids, other treatment options such as <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) or adrenocorticotropic hormone (ACTH) may be considered. These therapies are discussed elsewhere in this topic. (See <a class="local">'Treatment of resistant disease'</a> below.)</p><p></p><p>Patients receiving treatment for relapsing disease should be monitored using the same approach as those receiving initial therapy. (See <a class="local">'Monitoring and modifying therapy'</a> above.)</p><p>The treatment of relapse in patients with primary MN has not been evaluated in controlled trials.</p><p class="headingAnchor" id="H2551792927"><span class="h1">TREATMENT OF RESISTANT DISEASE</span><span class="headingEndMark"> — </span>Patients with primary MN who do not respond to initial therapy with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> plus glucocorticoids, or a calcineurin inhibitor (CNI) should be given an alternative regimen of one of these first-line therapies, as discussed elsewhere in this topic. (See <a class="local">'Monitoring and modifying therapy'</a> above.)</p><p>Patients who do not achieve a complete or partial remission after <strong>all</strong> of the first-line therapies have been tried are considered to have resistant disease. Among patients who are anti-phospholipase A2 receptor (PLA2R) antibody positive, persistence of serum anti-PLA2R antibodies in spite of immunosuppressive therapy is also indicative of resistant disease. The optimal approach to patients with resistant disease is not known, and in general, such patients should be referred to centers that have clinical experience in the treatment of patients with MN.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil (MMF) [<a href="#rid77">77-82</a>], natural adrenocorticotropic hormone (ACTH) gel [<a href="#rid62">62,83-87</a>], and plasma exchange [<a href="#rid88">88</a>] are reasonable therapeutic options, although high-quality data demonstrating their efficacy are lacking.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are resistant to <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> may respond to <a class="drug drug_general" data-topicid="91388" href="/z/d/drug information/91388.html" rel="external">obinutuzumab</a>, a more potent B cell–depleting antibody [<a href="#rid89">89,90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plasma cell–directed therapies (such as <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> and <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>) have been used with variable efficacy in case reports [<a href="#rid91">91,92</a>]. </p><p></p><p>In patients who are refractory to multiple immunosuppressive regimens, it may be difficult to distinguish between resistant disease and chronic, irreversible damage to the glomerular filtration barrier or the development of glomerulosclerosis. In such patients, a repeat kidney biopsy may be helpful to inform therapeutic decisions. Patients who are found on biopsy to have fresh immune deposits may potentially benefit from additional immunosuppressive therapy, whereas those with evidence of widespread, chronic histologic damage and no fresh immune deposits are unlikely to benefit from further immunosuppressive therapy.</p><p class="headingAnchor" id="H2285295799"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H312993538"><span class="h2">Patients with active infection</span><span class="headingEndMark"> — </span>In general, patients with primary MN who have an active infection should <strong>not </strong>be treated with immunosuppressive therapy. If the patient warrants immunosuppressive therapy but has not yet started treatment, we typically wait until the infection has resolved before initiating therapy. (See <a class="local">'High or very high risk of progression'</a> above.)</p><p>In patients with primary MN who develop an active infection while receiving immunosuppressive therapy, we temporarily withhold all immunosuppressive agents. We usually restart therapy when the patient has fully recovered from the infection.</p><p class="headingAnchor" id="H1125578019"><span class="h2">Patients with crescentic GN</span><span class="headingEndMark"> — </span>MN is infrequently associated with a crescentic glomerulonephritis (GN) that in some patients may be related to antineutrophil cytoplasmic antibodies (ANCA) or, less often, anti-glomerular basement membrane (GBM) antibodies. (See  <a class="medical medical_review" href="/z/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Crescentic glomerulonephritis'</a>.)</p><p>There is no high-quality evidence to guide the optimal therapeutic approach to patients with MN associated with a crescentic GN. Our approach in such patients is based on limited data from observational studies and our clinical experience:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with MN associated with crescentic GN who have evidence of ANCA or anti-GBM antibodies, we treat with immunosuppressive therapy using a similar approach as that for patients with crescentic GN associated with ANCA vasculitis or anti-GBM disease, respectively [<a href="#rid93">93-98</a>]. Treatment for these disorders is discussed in more detail elsewhere:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/3085.html" rel="external">"Anti-GBM (Goodpasture) disease: Treatment and prognosis", section on 'Initial therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with MN associated with crescentic GN who do <strong>not</strong> have evidence of ANCA or anti-GBM antibodies, we treat with immunosuppressive therapy given the generally poor prognosis of these patients [<a href="#rid99">99</a>]. We administer <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> or combination therapy with glucocorticoids plus <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> using a regimen similar to that used for initial therapy in patients with ANCA vasculitis. However, there are no high-quality data to support this or any other approach. (See  <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy"</a>.)</p><p></p><p class="headingAnchor" id="H2159255118"><span class="h2">Patients with primary MN and light chain-restricted deposits</span><span class="headingEndMark"> — </span>Rare cases of primary MN with light chain-restricted deposits have been reported. (See  <a class="medical medical_review" href="/z/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'MN with light chain–restricted deposits'</a>.)</p><p>The optimal management of patients with primary MN with light chain-restricted deposits is not known. In such patients, an evaluation for an underlying lymphoproliferative disorder should be performed, and, if a hematologic malignancy is diagnosed, appropriate treatment should be administered. Patients who have evidence of a pathologic B cell or plasma cell clone but do not meet criteria for a hematologic malignancy are considered to have monoclonal gammopathy of renal significance (MGRS). The treatment of patients with MGRS is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/109635.html" rel="external">"Diagnosis and treatment of monoclonal gammopathy of renal significance", section on 'Overview of our approach'</a>.)</p><p class="headingAnchor" id="H1554194011"><span class="h2">Patients who are pregnant</span><span class="headingEndMark"> — </span>Rare case reports of primary MN occurring in pregnant women have been described [<a href="#rid100">100,101</a>].</p><p>The optimal approach to the treatment of MN in pregnant patients is not known. As in nonpregnant patients with primary MN, we suggest an initial assessment to determine the patient's risk of disease progression (see <a class="local">'Which patients need treatment'</a> above). However, in pregnant patients with nephrotic syndrome, most authors of this topic would start immunosuppressive therapy. We prefer a CNI (<a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>) in those with normal or near-normal kidney function. In general, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> should be avoided in pregnant patients. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a>.)</p><p>Given the rarity of this clinical scenario, we suggest that pregnant patients with MN be referred to centers with expertise in the management of glomerular disease in pregnancy. Pregnant women with kidney disease should be jointly managed by a nephrologist and by a maternal-fetal medicine specialist. (See  <a class="medical medical_review" href="/z/d/html/7205.html" rel="external">"Pregnancy and contraception in patients with nondialysis chronic kidney disease", section on 'Management during pregnancy'</a>.)</p><p>A detailed discussion of pregnancy in women with underlying kidney disease and the general management of nephrotic syndrome in pregnancy are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7205.html" rel="external">"Pregnancy and contraception in patients with nondialysis chronic kidney disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4808.html" rel="external">"Proteinuria in pregnancy: Diagnosis, differential diagnosis, and management of nephrotic syndrome", section on 'Management of nephrotic syndrome in pregnancy'</a>.)</p><p></p><p class="headingAnchor" id="H4204270409"><span class="h1">TREATMENT OF SECONDARY MN</span><span class="headingEndMark"> — </span>Secondary MN has been attributed to a variety of agents and conditions  (<a class="graphic graphic_table graphicRef80418" href="/z/d/graphic/80418.html" rel="external">table 3</a>). In general, the treatment of secondary MN focuses on cessation of the offending drug or effective treatment of the underlying disease, which is usually associated with improvement in the nephrotic syndrome. (See  <a class="medical medical_review" href="/z/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Secondary MN'</a>.)</p><p>Some patients with secondary causes of MN may test positive for anti-phospholipase A2 receptor (PLA2R) antibodies. In such patients, the possibility of two separate disease entities, primary PLA2R-associated MN and a coincidental secondary disease (eg, hepatitis B virus [HBV] infection, malignancy), must be considered [<a href="#rid102">102</a>]. If the patient develops signs of progressively worsening MN (eg, declining kidney function, increasing proteinuria), we would administer immunosuppressive therapy, especially if the underlying secondary disease has already been successfully treated. Careful monitoring for recurrence or reactivation of the secondary disease should be performed. (See <a class="local">'Initial therapy for primary MN'</a> above.)</p><p>MN is the most common cause of the nephrotic syndrome that occurs following hematopoietic cell transplantation (HCT). Most patients are negative for anti-PLA2R antibodies; however rare cases of PLA2R-positive MN after HCT have been reported [<a href="#rid103">103</a>]. The treatment of MN after HCT is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7197.html" rel="external">"Kidney disease following hematopoietic cell transplantation", section on 'Membranous nephropathy'</a>.)</p><p class="headingAnchor" id="H2404257848"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Patients with primary MN who undergo spontaneous or drug-induced remission generally have a good long-term prognosis. Thirty to 40 percent of patients who receive cytotoxic therapy plus glucocorticoids undergo complete remission of proteinuria, 30 to 50 percent undergo partial remission, and the incidence of progressive kidney function impairment is only approximately 10 percent [<a href="#rid5">5,6,40</a>].</p><p>The prognosis after complete remission (whether treatment associated or spontaneous) was reported in 82 adults with biopsy-confirmed primary MN [<a href="#rid70">70</a>]. The mean total observation time was 101 months, 69 months of which was in the postremission period. Three distinct groups of patients were identified:</p><p class="bulletIndent1"><span class="glyph">●</span>Those who remained in remission (67 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Those with a remitting, relapsing course but without kidney function impairment (20 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Those who developed kidney function impairment (13 percent)</p><p></p><p>No patient subsequently developed end-stage kidney disease (ESKD). Multivariate analysis revealed that female sex and persistently low levels of proteinuria were associated with a durable remission. These parameters are also associated with a better long-term prognosis [<a href="#rid13">13</a>]. By comparison, progressive disease is characterized by persistent heavy proteinuria and a gradual elevation in the serum creatinine concentration over a period of years. As noted above, however, effective therapy can improve outcomes in such patients. (See <a class="local">'High or very high risk of progression'</a> above.)</p><p>Patients who attain partial remission have a much better outcome than those with stable or progressive disease. This was illustrated in an observational study that included 136 patients with primary MN who had partial remission and 110 who had no remission [<a href="#rid75">75</a>]. At a median of five years, partial remission was independently associated with a slower decrease in kidney function over time (-0.17 versus -0.86 mL/min per month with no remission) and a lower incidence of kidney failure (9 versus 29 percent, adjusted hazard ratio [HR] 0.17).</p><p>The durability of remission (spontaneous or treatment associated) is associated with improved kidney survival. One prospective study examined this relationship among 376 patients with primary MN who achieved complete or partial remission after a period of nephrotic-range proteinuria [<a href="#rid74">74</a>]. Persistent remission at 3, 6, 12, and 24 months after remission onset, compared with disease relapse at each of these time points, was associated with a significantly lower risk of the primary endpoint (ESKD or 50 percent reduction in estimated glomerular filtration rate [eGFR], HRs 0.48, 0.35, 0.37, and 0.40, respectively).</p><p class="headingAnchor" id="H2858603084"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a>.)</p><p class="headingAnchor" id="H3449645405"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures</strong> – General supportive measures in all patients with membranous nephropathy (MN) include blood pressure control, minimization of proteinuria with renin-angiotensin system inhibition, treatment of dyslipidemia, and, in select patients, anticoagulation. Other aspects of therapy include dietary sodium restriction, diuretics to control edema, and maintenance of adequate nutrition. (See <a class="local">'General measures in all patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk assessment</strong> – Since many patients with mild to moderate disease undergo spontaneous remission  (<a class="graphic graphic_figure graphicRef61059" href="/z/d/graphic/61059.html" rel="external">figure 2</a>) and immunosuppressive agents have appreciable toxicity, most experts agree that treatment with immunosuppressive therapy should be reserved for those who are at highest risk for developing progressive kidney failure. In patients with primary MN, our approach to initial therapy is based upon an initial assessment of the patient's risk of progressive disease (eg, very high, high, moderate, or low), which we determine using both clinical and immunologic parameters  (<a class="graphic graphic_table graphicRef126999" href="/z/d/graphic/126999.html" rel="external">table 1</a>). (See <a class="local">'Which patients need treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High or very high risk of progression</strong> – In patients who are at high or very high risk of progression, we recommend treatment with immunosuppressive therapy and continued general supportive measures, rather than continued general supportive measures alone (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). The choice of immunosuppressive therapy depends upon how the patient is defined as high or very high risk (see <a class="local">'High or very high risk of progression'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients who are classified as high or very high risk and have stable kidney function, we suggest treatment with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> rather than cytotoxic therapy or other therapies (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, a calcineurin inhibitor (CNI) is a reasonable alternative to rituximab in patients who are anti-phospholipase A2 receptor (PLA2R) antibody negative. (See <a class="local">'Rituximab'</a> above and <a class="local">'Cytotoxic therapy plus glucocorticoids'</a> above and <a class="local">'Calcineurin inhibitors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients who are classified as high or very high risk because of abnormal or declining kidney function at presentation <strong>or </strong>rapidly declining kidney function due to MN, we suggest combination treatment with glucocorticoids and a cytotoxic agent (preferably <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>) rather than <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> or other therapies (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In patients who wish to avoid cytotoxic therapy, treatment with rituximab may be a reasonable alternative.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate risk of progression</strong> – In patients who are at moderate risk of progression, our approach to initial therapy varies depending upon the course of disease during an initial three-to-six-month observation period with maximal general supportive measures (including renin-angiotensin system inhibition) (see <a class="local">'Moderate risk of progression'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In moderate-risk patients who show a progressive increase in proteinuria over the observation period, we recommend treatment with immunosuppressive therapy and continued general supportive measures, rather than continued general supportive measures alone (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In moderate-risk patients who show stable proteinuria over the observation period, we suggest immunosuppressive therapy and continued general supportive measures, rather than continued general supportive measures alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, some clinicians would continue to withhold immunosuppressive therapy beyond six months in such patients if they are doing well, serum albumin is increasing, anti-PLA2R antibody levels (if initially positive) are low or decreasing, or if the patients are at high risk of having an adverse event with immunosuppressive therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In moderate-risk patients who show a progressive decline in proteinuria over the observation period, we withhold immunosuppression and continue general supportive measures.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In most moderate-risk patients who require immunosuppressive therapy, we suggest <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> rather than glucocorticoids plus cytotoxic therapy or a CNI (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). If rituximab is unavailable, <strong>either</strong> combination therapy with glucocorticoids plus a cytotoxic agent <strong>or</strong> CNI monotherapy is a reasonable alternative. If cytotoxic therapy is chosen, we prefer <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> over <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a>, since chlorambucil has more side effects. If a CNI is selected, either <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> is a reasonable choice. (See <a class="local">'Rituximab'</a> above and <a class="local">'Cytotoxic therapy plus glucocorticoids'</a> above and <a class="local">'Calcineurin inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low risk of progression</strong> – Patients at low risk of progression do not require immunosuppressive therapy and can be managed with continued observation and general supportive measures only. Such patients generally have excellent long-term prognosis and often undergo spontaneous partial or complete remission. (See <a class="local">'Low risk of progression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – All patients who are receiving treatment for primary MN should be closely monitored for clinical response to therapy. In patients with PLA2R-associated primary MN, serial assessment of anti-PLA2R antibody levels may be useful for monitoring the immunologic activity of disease and guiding treatment decisions. (See <a class="local">'Monitoring and modifying therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapsing disease</strong> – In patients who develop a relapse, we suggest a six-month observation period with general supportive measures to reassess the risk for progressive disease, using the same approach as that for newly diagnosed patients with primary MN. In patients who require immunosuppressive therapy, the choice of agent for relapse depends upon the initial immunosuppressive regimen. (See <a class="local">'Treatment of relapsing disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistant disease</strong> – The optimal approach to patients with resistant disease is not known. <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil (MMF), natural adrenocorticotropic hormone (ACTH) gel, and plasma exchange are reasonable therapeutic options, although high-quality data demonstrating their efficacy are lacking. In general, patients with resistant disease should be referred to centers that have clinical expertise in the treatment of patients with MN. (See <a class="local">'Treatment of resistant disease'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sethi S. New 'Antigens' in Membranous Nephropathy. J Am Soc Nephrol 2021; 32:268.</a></li><li><a class="nounderline abstract_t">van de Logt AE, Dahan K, Rousseau A, et al. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. Kidney Int 2018; 93:1016.</a></li><li><a class="nounderline abstract_t">Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 1995; 25:862.</a></li><li><a class="nounderline abstract_t">Schieppati A, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993; 329:85.</a></li><li><a class="nounderline abstract_t">Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995; 48:1600.</a></li><li><a class="nounderline abstract_t">Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007; 18:1899.</a></li><li><a class="nounderline abstract_t">Rodas LM, Matas-García A, Barros X, et al. Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy. Clin Kidney J 2019; 12:36.</a></li><li><a class="nounderline abstract_t">Hladunewich MA, Troyanov S, Calafati J, et al. The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol 2009; 4:1417.</a></li><li><a class="nounderline abstract_t">Shiiki H, Saito T, Nishitani Y, et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int 2004; 65:1400.</a></li><li><a class="nounderline abstract_t">Glassock RJ. Diagnosis and natural course of membranous nephropathy. Semin Nephrol 2003; 23:324.</a></li><li><a class="nounderline abstract_t">Pei Y, Cattran D, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 1992; 42:960.</a></li><li><a class="nounderline abstract_t">Cattran DC, Pei Y, Greenwood CM, et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 1997; 51:901.</a></li><li><a class="nounderline abstract_t">Cattran DC, Reich HN, Beanlands HJ, et al. The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 2008; 23:2247.</a></li><li><a class="nounderline abstract_t">Troyanov S, Roasio L, Pandes M, et al. Renal pathology in idiopathic membranous nephropathy: a new perspective. Kidney Int 2006; 69:1641.</a></li><li><a class="nounderline abstract_t">Reichert LJ, Koene RA, Wetzels JF. Prognostic factors in idiopathic membranous nephropathy. Am J Kidney Dis 1998; 31:1.</a></li><li><a class="nounderline abstract_t">Polanco N, Gutiérrez E, Covarsí A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010; 21:697.</a></li><li><a class="nounderline abstract_t">Pourcine F, Dahan K, Mihout F, et al. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years. PLoS One 2017; 12:e0173201.</a></li><li><a class="nounderline abstract_t">Timmermans SA, Abdul Hamid MA, Cohen Tervaert JW, et al. Anti-PLA2R Antibodies as a Prognostic Factor in PLA2R-Related Membranous Nephropathy. Am J Nephrol 2015; 42:70.</a></li><li><a class="nounderline abstract_t">Kanigicherla D, Gummadova J, McKenzie EA, et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 2013; 83:940.</a></li><li><a class="nounderline abstract_t">Hoxha E, Harendza S, Pinnschmidt H, et al. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol 2014; 9:1883.</a></li><li><a class="nounderline abstract_t">Mahmud M, Pinnschmidt HO, Reinhard L, et al. Role of phospholipase A2 receptor 1 antibody level at diagnosis for long-term renal outcome in membranous nephropathy. PLoS One 2019; 14:e0221293.</a></li><li><a class="nounderline abstract_t">Hofstra JM, Debiec H, Short CD, et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23:1735.</a></li><li><a class="nounderline abstract_t">Hoxha E, Harendza S, Pinnschmidt H, et al. PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system. PLoS One 2014; 9:e110681.</a></li><li><a class="nounderline abstract_t">Jullien P, Seitz Polski B, Maillard N, et al. Anti-phospholipase A2 receptor antibody levels at diagnosis predicts spontaneous remission of idiopathic membranous nephropathy. Clin Kidney J 2017; 10:209.</a></li><li><a class="nounderline abstract_t">Hoxha E, Harendza S, Pinnschmidt HO, et al. Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy. Nephrol Dial Transplant 2015; 30:1862.</a></li><li><a class="nounderline abstract_t">Radice A, Trezzi B, Maggiore U, et al. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Autoimmun Rev 2016; 15:146.</a></li><li><a class="nounderline abstract_t">Hoxha E, Beck LH Jr, Wiech T, et al. An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy. J Am Soc Nephrol 2017; 28:520.</a></li><li><a class="nounderline abstract_t">Zaghrini C, Seitz-Polski B, Justino J, et al. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. Kidney Int 2019; 95:666.</a></li><li><a class="nounderline abstract_t">Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014; 371:2277.</a></li><li><a class="nounderline abstract_t">Branten AJ, du Buf-Vereijken PW, Klasen IS, et al. Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol 2005; 16:169.</a></li><li><a class="nounderline abstract_t">van den Brand JA, Hofstra JM, Wetzels JF. Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011; 6:2846.</a></li><li><a class="nounderline abstract_t">Wakai S, Magil AB. Focal glomerulosclerosis in idiopathic membranous glomerulonephritis. Kidney Int 1992; 41:428.</a></li><li><a class="nounderline abstract_t">Wu Q, Jinde K, Nishina M, et al. Analysis of prognostic predictors in idiopathic membranous nephropathy. Am J Kidney Dis 2001; 37:380.</a></li><li><a class="nounderline abstract_t">Floege J, Barbour SJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019; 95:268.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:S1.</a></li><li><a class="nounderline abstract_t">De Vriese AS, Glassock RJ, Nath KA, et al. A Proposal for a Serology-Based Approach to Membranous Nephropathy. J Am Soc Nephrol 2017; 28:421.</a></li><li><a class="nounderline abstract_t">Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med 2019; 381:36.</a></li><li><a class="nounderline abstract_t">Howman A, Chapman TL, Langdon MM, et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 2013; 381:744.</a></li><li><a class="nounderline abstract_t">Dahan K, Johannet C, Esteve E, et al. Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody. Kidney Int 2019; 95:233.</a></li><li><a class="nounderline abstract_t">Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9:444.</a></li><li><a class="nounderline abstract_t">Zhu LB, Liu LL, Yao L, Wang LN. Efficacy and Safety of Tacrolimus Versus Cyclophosphamide for Primary Membranous Nephropathy: A Meta-Analysis. Drugs 2017; 77:187.</a></li><li><a class="nounderline abstract_t">Qiu TT, Zhang C, Zhao HW, Zhou JW. Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials. Autoimmun Rev 2017; 16:136.</a></li><li><a class="nounderline abstract_t">Fernández-Juárez G, Rojas-Rivera J, Logt AV, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int 2021; 99:986.</a></li><li><a class="nounderline abstract_t">Dahan K, Debiec H, Plaisier E, et al. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. J Am Soc Nephrol 2017; 28:348.</a></li><li><a class="nounderline abstract_t">Fervenza FC, Abraham RS, Erickson SB, et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 2010; 5:2188.</a></li><li><a class="nounderline abstract_t">Remuzzi G, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy. Lancet 2002; 360:923.</a></li><li><a class="nounderline abstract_t">Ruggenenti P, Chiurchiu C, Brusegan V, et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003; 14:1851.</a></li><li><a class="nounderline abstract_t">Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. J Am Soc Nephrol 2015; 26:2545.</a></li><li><a class="nounderline abstract_t">Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008; 73:117.</a></li><li><a class="nounderline abstract_t">Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007; 2:932.</a></li><li><a class="nounderline abstract_t">Ruggenenti P, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 2006; 1:738.</a></li><li><a class="nounderline abstract_t">Segarra A, Praga M, Ramos N, et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 2009; 4:1083.</a></li><li><a class="nounderline abstract_t">Busch M, Rüster C, Schinköthe C, et al. Rituximab for the second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy. Clin Nephrol 2013; 80:105.</a></li><li><a class="nounderline abstract_t">Scolari F, Delbarba E, Santoro D, et al. Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. J Am Soc Nephrol 2021; 32:972.</a></li><li><a class="nounderline abstract_t">Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23:1416.</a></li><li><a class="nounderline abstract_t">Cattran DC, Appel GB, Hebert LA, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001; 59:1484.</a></li><li><a class="nounderline abstract_t">Praga M, Barrio V, Juárez GF, et al. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int 2007; 71:924.</a></li><li><a class="nounderline abstract_t">Zheng Q, Yang H, Liu W, et al. Comparative efficacy of 13 immunosuppressive agents for idiopathic membranous nephropathy in adults with nephrotic syndrome: a systematic review and network meta-analysis. BMJ Open 2019; 9:e030919.</a></li><li><a class="nounderline abstract_t">Lin W, Li HY, Lin S, Zhou T. Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis. Drug Des Devel Ther 2019; 13:2179.</a></li><li><a class="nounderline abstract_t">Li YC, Huang J, Li X, Zhao SM. A comparison of cyclophosphamide versus tacrolimus in terms of treatment effect for idiopathic membranous nephropathy: A meta-analysis. Nefrologia (Engl Ed) 2019; 39:269.</a></li><li><a class="nounderline abstract_t">Ramachandran R, Hn HK, Kumar V, et al. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial. Nephrology (Carlton) 2016; 21:139.</a></li><li><a class="nounderline abstract_t">Ponticelli C, Passerini P, Salvadori M, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 2006; 47:233.</a></li><li><a class="nounderline abstract_t">van den Brand JAJG, Ruggenenti P, Chianca A, et al. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. J Am Soc Nephrol 2017; 28:2729.</a></li><li><a class="nounderline abstract_t">Beck LH Jr, Fervenza FC, Beck DM, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011; 22:1543.</a></li><li><a class="nounderline abstract_t">Ramachandran R, Kumar V, Nada R, Jha V. Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy. Kidney Int 2015; 88:1198.</a></li><li><a class="nounderline abstract_t">Wei SY, Wang YX, Li JS, et al. Serum Anti-PLA2R Antibody Predicts Treatment Outcome in Idiopathic Membranous Nephropathy. Am J Nephrol 2016; 43:129.</a></li><li><a class="nounderline abstract_t">Bech AP, Hofstra JM, Brenchley PE, Wetzels JF. Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2014; 9:1386.</a></li><li><a class="nounderline abstract_t">Medrano AS, Escalante EJ, Cáceres CC, et al. Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens. Biomarkers 2015; 20:77.</a></li><li><a class="nounderline abstract_t">Vink CH, Logt AV, van der Molen RG, et al. Antibody-Guided Therapy in Phospholipase A2 Receptor-Associated Membranous Nephropathy. Kidney Int Rep 2023; 8:432.</a></li><li><a class="nounderline abstract_t">Laluck BJ Jr, Cattran DC. Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. Am J Kidney Dis 1999; 33:1026.</a></li><li><a class="nounderline abstract_t">du Buf-Vereijken PW, Wetzels JF. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity. Nephrol Dial Transplant 2004; 19:2036.</a></li><li><a class="nounderline abstract_t">du Buf-Vereijken PW, Branten AJ, Wetzels JF, Membranous Nephropathy Study Group. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. Nephrol Dial Transplant 2004; 19:1142.</a></li><li><a class="nounderline abstract_t">Kanigicherla DA, Short CD, Roberts SA, et al. Long-term outcomes of persistent disease and relapse in primary membranous nephropathy. Nephrol Dial Transplant 2016; 31:2108.</a></li><li><a class="nounderline abstract_t">Cattran DC, Kim ED, Reich H, et al. Membranous Nephropathy: Quantifying Remission Duration on Outcome. J Am Soc Nephrol 2017; 28:995.</a></li><li><a class="nounderline abstract_t">Troyanov S, Wall CA, Miller JA, et al. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 2004; 66:1199.</a></li><li><a class="nounderline abstract_t">Thompson A, Cattran DC, Blank M, Nachman PH. Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy. J Am Soc Nephrol 2015; 26:2930.</a></li><li><a class="nounderline abstract_t">Miller G, Zimmerman R 3rd, Radhakrishnan J, Appel G. Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 2000; 36:250.</a></li><li><a class="nounderline abstract_t">Choi MJ, Eustace JA, Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61:1098.</a></li><li><a class="nounderline abstract_t">Branten AJ, du Buf-Vereijken PW, Vervloet M, Wetzels JF. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 2007; 50:248.</a></li><li><a class="nounderline abstract_t">Chan TM, Lin AW, Tang SC, et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology (Carlton) 2007; 12:576.</a></li><li><a class="nounderline abstract_t">Senthil Nayagam L, Ganguli A, Rathi M, et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant 2008; 23:1926.</a></li><li><a class="nounderline abstract_t">Appel GB, Radhakrishnan J, Ginzler E. Use of mycophenolate mofetil in glomerular diseases. Transplantation 2005; 80(Suppl 2):8265.</a></li><li><a class="nounderline abstract_t">Lorusso P, Bottai A, Mangione E, et al. Low-dose synthetic adrenocorticotropic hormone-analog therapy for nephrotic patients: results from a single-center pilot study. Int J Nephrol Renovasc Dis 2015; 8:7.</a></li><li><a class="nounderline abstract_t">van de Logt AE, Beerenhout CH, Brink HS, et al. Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study. PLoS One 2015; 10:e0142033.</a></li><li><a class="nounderline abstract_t">Hladunewich MA, Cattran D, Beck LH, et al. A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy. Nephrol Dial Transplant 2014; 29:1570.</a></li><li><a class="nounderline abstract_t">Bomback AS, Tumlin JA, Baranski J, et al. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des Devel Ther 2011; 5:147.</a></li><li><a class="nounderline abstract_t">Bomback AS, Canetta PA, Beck LH Jr, et al. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am J Nephrol 2012; 36:58.</a></li><li><a class="nounderline abstract_t">Müller-Deile J, Schiffer L, Hiss M, et al. A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis. Eur J Clin Invest 2015; 45:1260.</a></li><li><a class="nounderline abstract_t">Klomjit N, Fervenza FC, Zand L. Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases. Am J Kidney Dis 2020; 76:883.</a></li><li><a class="nounderline abstract_t">Sethi S, Kumar S, Lim K, Jordan SC. Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy. Kidney Int Rep 2020; 5:1515.</a></li><li><a class="nounderline abstract_t">Stehlé T, Grimbert P, Remy P, et al. Anti-CD38 therapy for PLA2R-positive membranous nephropathy resistant to conventional immunosuppression. Kidney Int 2022; 101:416.</a></li><li><a class="nounderline abstract_t">Salhi S, Ribes D, Colombat M, et al. Bortezomib plus dexamethasone for rituximab-resistant PLA2R+ membranous nephropathy. Kidney Int 2021; 100:708.</a></li><li><a class="nounderline abstract_t">Nasr SH, Said SM, Valeri AM, et al. Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis. Clin J Am Soc Nephrol 2009; 4:299.</a></li><li><a class="nounderline abstract_t">Dwyer KM, Agar JW, Hill PA, Murphy BF. Membranous nephropathy and anti-neutrophil cytoplasmic antibody-associated glomerulonephritis: a report of 2 cases. Clin Nephrol 2001; 56:394.</a></li><li><a class="nounderline abstract_t">Sano T, Kamata K, Shigematsu H, Kobayashi Y. A case of anti-glomerular basement membrane glomerulonephritis superimposed on membranous nephropathy. Nephrol Dial Transplant 2000; 15:1238.</a></li><li><a class="nounderline abstract_t">James SH, Lien YH, Ruffenach SJ, Wilcox GE. Acute renal failure in membranous glomerulonephropathy: a result of superimposed crescentic glomerulonephritis. J Am Soc Nephrol 1995; 6:1541.</a></li><li><a class="nounderline abstract_t">Tse WY, Howie AJ, Adu D, et al. Association of vasculitic glomerulonephritis with membranous nephropathy: a report of 10 cases. Nephrol Dial Transplant 1997; 12:1017.</a></li><li><a class="nounderline abstract_t">Nikolopoulou A, Huang-Doran I, McAdoo SP, et al. Membranous Glomerulonephritis With Crescents. Kidney Int Rep 2019; 4:1577.</a></li><li><a class="nounderline abstract_t">Rodriguez EF, Nasr SH, Larsen CP, et al. Membranous nephropathy with crescents: a series of 19 cases. Am J Kidney Dis 2014; 64:66.</a></li><li><a class="nounderline abstract_t">Iwakura T, Fujigaki Y, Katahashi N, et al. Membranous Nephropathy with an Enhanced Granular Expression of Thrombospondin Type-1 Domain-containing 7A in a Pregnant Woman. Intern Med 2016; 55:2663.</a></li><li><a class="nounderline abstract_t">Aoshima Y, Iyoda M, Nakazawa A, et al. Membranous nephropathy that first presented in pregnancy. Intern Med 2013; 52:1949.</a></li><li><a class="nounderline abstract_t">Qin W, Beck LH Jr, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 2011; 22:1137.</a></li><li><a class="nounderline abstract_t">Huang X, Qin W, Zhang M, et al. Detection of anti-PLA2R autoantibodies and IgG subclasses in post-allogeneic hematopoietic stem cell transplantation membranous nephropathy. Am J Med Sci 2013; 346:32.</a></li></ol></div><div id="topicVersionRevision">Topic 3051 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33380523" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : New 'Antigens' in Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29571438" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7771482" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A review of therapeutic studies of idiopathic membranous glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8510707" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prognosis of untreated patients with idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8544420" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17494881" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30747150" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19661220" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The natural history of the non-nephrotic membranous nephropathy patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15086481" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12923720" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Diagnosis and natural course of membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1453588" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9067928" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18182409" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The impact of sex in primary glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16572119" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Renal pathology in idiopathic membranous nephropathy: a new perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9428445" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prognostic factors in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20110379" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28257452" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26344651" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Anti-PLA2R Antibodies as a Prognostic Factor in PLA2R-Related Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23364522" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25267554" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31498806" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Role of phospholipase A2 receptor 1 antibody level at diagnosis for long-term renal outcome in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22956816" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25313791" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28396737" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Anti-phospholipase A2 receptor antibody levels at diagnosis predicts spontaneous remission of idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26142398" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26527329" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27436855" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30784662" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25394321" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15563570" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22157712" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1552716" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Focal glomerulosclerosis in idiopathic membranous glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157381" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Analysis of prognostic predictors in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30665568" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34556256" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27777266" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A Proposal for a Serology-Based Approach to Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31269364" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23312808" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30606419" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9513907" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28084563" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy and Safety of Tacrolimus Versus Cyclophosphamide for Primary Membranous Nephropathy: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27988429" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33166580" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27352623" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20705965" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12354476" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Rituximab for idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12819245" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Rituximab in idiopathic membranous nephropathy: a one-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25804280" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17943078" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Rituximab treatment of idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17702725" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699281" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Rituximab for idiopathic membranous nephropathy: who can benefit?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19478097" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23587125" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Rituximab for the second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33649098" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22822077" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Rituximab in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11260412" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17377504" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31511292" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comparative efficacy of 13 immunosuppressive agents for idiopathic membranous nephropathy in adults with nephrotic syndrome: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31308629" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30755327" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A comparison of cyclophosphamide versus tacrolimus in terms of treatment effect for idiopathic membranous nephropathy: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26205759" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16431252" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28487395" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21784898" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26579688" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27058841" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Serum Anti-PLA2R Antibody Predicts Treatment Outcome in Idiopathic Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25035272" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25519165" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36938074" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Antibody-Guided Therapy in Phospholipase A2 Receptor-Associated Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10352189" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15187191" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14993502" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26769682" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Long-term outcomes of persistent disease and relapse in primary membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27756808" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Membranous Nephropathy: Quantifying Remission Duration on Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15327418" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Idiopathic membranous nephropathy: definition and relevance of a partial remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26078365" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10922302" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Use of mycophenolate mofetil in resistant membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11849465" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Mycophenolate mofetil treatment for primary glomerular diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17660026" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17995584" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17989103" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Use of mycophenolate mofetil in glomerular diseases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25709493" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Low-dose synthetic adrenocorticotropic hormone-analog therapy for nephrotic patients: results from a single-center pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26562836" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24714414" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar®Gel) in nephrotic syndrome due to idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21448451" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22722778" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26444294" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32311405" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32954076" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35065692" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Anti-CD38 therapy for PLA2R-positive membranous nephropathy resistant to conventional immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34420663" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Bortezomib plus dexamethasone for rituximab-resistant PLA2R+ membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19158367" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11758012" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Membranous nephropathy and anti-neutrophil cytoplasmic antibody-associated glomerulonephritis: a report of 2 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10910453" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A case of anti-glomerular basement membrane glomerulonephritis superimposed on membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8749678" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Acute renal failure in membranous glomerulonephropathy: a result of superimposed crescentic glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9175062" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Association of vasculitic glomerulonephritis with membranous nephropathy: a report of 10 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31890999" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Membranous Glomerulonephritis With Crescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24709471" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Membranous nephropathy with crescents: a series of 19 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27629964" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Membranous Nephropathy with an Enhanced Granular Expression of Thrombospondin Type-1 Domain-containing 7A in a Pregnant Woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23994989" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Membranous nephropathy that first presented in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21566055" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Anti-phospholipase A2 receptor antibody in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23103439" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Detection of anti-PLA2R autoantibodies and IgG subclasses in post-allogeneic hematopoietic stem cell transplantation membranous nephropathy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
